Article
A biomarker panel and psychological morbidity differentiates the irritable bowel syndrome from health and provides novel pathophysiological leads
6 Jan 2014
Abstract excerpt
BACKGROUNDS: The development of a reliable biomarker for irritable bowel syndrome (IBS) remains one of the major aims of research in functional gastrointestinal disorders (FGIDs) and is complicated by the absence of a perfect reference standard. Previous efforts based on genetic and immune markers have showed promise, but have not been robust. AIM: To evaluate an extensive panel of gene expression and serology...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
